Patents by Inventor Freda K. Stevenson

Freda K. Stevenson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HER2/Neu cancer vaccine
    Patent number: 10052370
    Abstract: Protein conjugate comprising a protein antigen for generating an immune response against the HER2/neu protein and an immunogenic carrier covalently bonded to said protein antigen, wherein said protein antigen (i) has a sequence segment of 300 or more contiguous amino acids of the amino acid sequence of SEQ ID NO: 1; or (ii) has a variant sequence segment of 300 or more amino acid residues, wherein the amino acid sequence of said variant sequence segment has at least 85% sequence identity to a sequence portion from SEQ ID: 1; or (iii) has a variant sequence segment of 300 or more amino acid residues and has from 1 to 10 substitutions, deletions or additions in said variant sequence segment compared to a sequence segment of 300 or more amino acid residues of the amino acid sequence of SEQ ID NO: 1 or 2.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: August 21, 2018
    Assignees: ICON GENETICS GMBH, UNIVERSITY OF SOUTHAMPTON
    Inventors: Natalia Savelyeva, Franziska Jarczowski, Romy Kandzia, Anja Nickstadt, Frank Thieme, Victor Klimyuk, Yuri Gleba, Duc Bui-Minh, Freda K. Stevenson, Warayut Chotprakaikiat
  • HER2/NEU CANCER VACCINE
    Publication number: 20160015796
    Abstract: Protein conjugate comprising a protein antigen for generating an immune response against the HER2/neu protein and an immunogenic carrier covalently bonded to said protein antigen, wherein said protein antigen (i) has a sequence segment of 300 or more contiguous amino acids of the amino acid sequence of SEQ ID NO: 1; or (ii) has a variant sequence segment of 300 or more amino acid residues, wherein the amino acid sequence of said variant sequence segment has at least 85% sequence identity to a sequence portion from SEQ ID: 1; or (iii) has a variant sequence segment of 300 or more amino acid residues and has from 1 to 10 substitutions, deletions or additions in said variant sequence segment compared to a sequence segment of 300 or more amino acid residues of the amino acid sequence of SEQ ID NO: 1 or 2.
    Type: Application
    Filed: March 11, 2014
    Publication date: January 21, 2016
    Applicants: ICON GENETICS GMBH, UNIVERSITY OF SOUTHAMPTON
    Inventors: Natalia Savelyeva, Franziska Jarczowski, Romy Kandzia, Anja Nickstadt, Frank Thieme, Victor Klimyuk, Yuri Gleba, Duc Bui-Minh, Freda K. Stevenson, Warayut Chotprakaikiat
  • Immune responses to fusion proteins
    Patent number: 6936464
    Abstract: The invention relates to a nucleic acid construct for delivery into living cells in vivo for inducing an immune response in a patient to an idiotypic determinant present on a malignant B cell in the patient; the construct directing the expression of a fusion protein, said fusion protein comprising the idiotypic determinant and at least one T helper cell epitope from tetanus toxin. The invention further relates to a method of making the nucleic acid construct, a method of treating a patient, and to a composition comprising the nucleic acid construct.
    Type: Grant
    Filed: July 18, 1997
    Date of Patent: August 30, 2005
    Assignee: Cancer Research Technology Limited
    Inventors: Delin Zhu, Robert E Hawkins, Stephen J. Russell, Freda K. Stevenson, Gregory P Winter